

# HEALTHIER CHINA THROUGH INNOVATION 创新引领健康中国



中国外商投资企业协会药品研制和开发行业委员会  
China Association of Enterprises with Foreign Investment  
R&D-based Pharmaceutical Association Committee




# ABOUT RDPAC

The R&D-based Pharmaceutical Association Committee (RDPAC) is a committee of the China Association of Enterprises with Foreign Investment (CAEFI). It is a non-profit organization made up of 42 member companies with pharmaceutical R&D capabilities. As of June 2020, RDPAC members have 47 plants and 25 R&D centres in mainland China.

## 关于RDPAC

RDPAC 是一个由42家具备研究开发能力的跨国制药企业组成的非赢利性组织，隶属于“中国外商投资企业协会”。截至2020年6月，RDPAC 成员已在中国大陆设立了47家生产工厂，25个研发中心。



## RDPAC VISION - HEALTHIER CHINA THROUGH INNOVATION

RDPAC's vision is to be a valued partner in delivering the "Healthy China" goal to improve the health and quality of life of the people in China:

- Provide our high-quality/innovative healthcare products and services in a socially responsible and commercially viable manner;
- Commit to securing patients timely access to innovative and high quality drugs;
- Achieve the highest standard of integrity for ethical research and business practice;
- Contribute to the growth of the biopharmaceutical sector in China;
- Support the development of a sustainable healthcare system in China.

## 愿景 – 创新引领健康中国

致力于成为中国实现“健康中国”目标以及不断提高居民和患者生活质量的重要合作伙伴：


- 兼顾社会责任与行业发展，为中国提供高质量的、创新的医疗健康产品和服务；
- 为确保患者及时获得质优及创新药品而努力；
- 在研究和商业运营中保持诚信，遵循最高标准道德规范；
- 对中国生物制药产业的发展做出积极的贡献；
- 支持中国建立可持续发展的医疗卫生体系。



The Chinese government has boldly committed to moving the pharmaceutical industry up the value chain towards innovation and has made good progress towards this ambitious goal.

中国政府正在全力提高医药产业的创新能力，并且已经取得一系列的卓越成绩

# 1



# 2

RDPAC members have been long-term innovation partners with China through continuous contributions to patient safety, drug quality and treatment standards for Chinese patients.

长期以来，RDPAC 成员一直是中国医药产业的创新合作伙伴，在提升用药安全、药物质量以及治疗标准等方面作出了持续的贡献





Pharmaceutical R&D innovation today is conducted through global networks, and RDPAC members are integrating China into the global R&D innovation system.

在全球性合作引领医药产业研发创新的今天，RDPAC成员有力地推动了中国融入全球医药创新体系的步伐

3



# 4

RDPAC members have rapidly increased their investments in China R&D to 12.2 billion RMB per year, accounting for >50% of China's large and mid-size pharmaceutical industry R&D spending and creating ~ 6,000 R&D positions.

RDPAC 成员在中国的研发创新投入正在大幅度提高，目前总投入水平已达到每年122亿元人民币，超过中国所有大中型医药企业一年研发支出总投入的一半，并直接创造了约6,000个研发岗位



RDPAC members are helping to build innovative local Chinese companies by developing expertise, seeding talent and taking them global.

RDPAC 成员通过提升科研技术水平、培育高级管理人才以及协助拓展国际市场，有力推进了中国创新型本土企业的发展

6





# 7

To become a truly global innovator, in addition to making steady progress towards a thriving scientific infrastructure, China needs to provide a supportive regulatory environment, reward innovation and continue to protect IPR.

展望未来，中国要成为真正的全球创新者，不仅需要提供不断完善的基础研发配套设施，更要注重建立支持创新的监管环境、制定合理的创新激励机制以及加大对知识产权的保护力度



The Chinese government, local companies and RDPAC members share a similar vision to see China become a leading global innovation partner. RDPAC welcomes the opportunity to continue to partner with the government to reach our joint aspiration for the benefit of Chinese patients.

中国政府、本土企业以及RDPAC成员怀有一个共同的愿望，即希望中国成为全球医药创新的领军者。RDPAC期待有机会和中国政府共同努力、协同发展，实现这一愿望，惠及更多中国患者

# 8



# RDPAC 42 Members – Landscape

## RDPAC成员概览



### Beijing 北京 (13)

Astellas	安斯泰来
Bayer HealthCare	拜耳医药保健
Chugai	中外制药
Helsinn	赫尔森
Ipsen	益普生
Lundbeck	灵北
Merck Serono	默克雪兰诺
Mundipharma	萌蒂制药
Novo Nordisk	诺和诺德
Pfizer	辉瑞
Servier	施维雅
Takeda	武田
Xian-Janssen	西安杨森


### Shanghai 上海 (29)

Abbott	雅培	Gedeon Richter Plc.	吉瑞大药厂
AbbVie	艾伯维	Gilead	吉利德
Allergan	艾尔建	GSK	葛兰素史克
Amgen	安进	Kyowa Kirin	协和发酵麒麟
AstraZeneca	阿斯利康	LEO Pharma	利奥制药
Baxter	百特	Menarini	美纳里尼
Biogen	渤健	MSD	默沙东
Bristol-Myers Squibb	百时美施贵宝	Novartis	诺华
Boehringer Ingelheim	勃林格殷格翰	Roche	罗氏
Chiesi	凯西	Sanofi	赛诺菲
Daiichi Sankyo	第一三共	Santen	参天制药
Eisai	卫材	Sumitomo	住友
Eli Lilly	礼来	Teva	梯瓦
Ethypharm	爱的发制药	UCB	优时比制药
		Zambon	赞邦

# RDPAC Members 25 R&D Centre's

## RDPAC成员在华设立了25个研发中心

City	# of R&D Centers
Shanghai上海	11
Beijing北京	8
Suzhou苏州	4
Wuhan武汉	1
Chengdu成都	1






# RDPAC Members 47 Plants

RDPAC成员在华设立了47家工厂

City	# of Plants
Shanghai上海	9
Suzhou苏州	7
Tianjin天津	6
Beijing北京	5
Hangzhou杭州	4
Guangzhou广州	2
Wuxi无锡	2
Taizhou泰州	2
Ningbo宁波	1
Nantong南通	1
Shenyang沈阳	1
Chongqing重庆	1

City	# of Plants
Dalian大连	1
Shenzhen深圳	1
Zhuhai珠海	1
Xian西安	1
Benxi本溪	1
Zhongshan中山	1



THANK YOU !

谢 谢!

[www.rdpac.org](http://www.rdpac.org)

R&D based Pharmaceutical Association Committee, Rm 506, Office Building 1, Landmark Tower,  
No.9 North Dongsanhuan Road, Chaoyang District, Beijing 100004, China. +8610-6590 7696

Legal Notice: The information contained in this communication is intended solely for the use of the individual or entity to whom it is addressed and others authorized to receive it. It may contain confidential or legally privileged information. If you are not the intended recipient you are hereby notified that any disclosure, copying, distribution or taking any action in reliance on the contents of this information is strictly prohibited and may be illegal. If you have received this communication in error, please notify us immediately by responding to this email and then delete it from your system. RDPAC is neither liable for the proper and complete transmission of the information contained in this communication nor for any delay in its receipt.

